

NCODA International Spring Forum

April 27-29, 2022 | Atlanta, Marriott Marquis, Atlanta, GA

Jointly provided by Partners for Advancing Clinical Education (PACE) and NCODA

Target Audience

This activity is intended for oncology healthcare providers that include; pharmacists, pharmacy technicians, physicians and nurses who care for patients within oncology.

Individual CME/CNE Session Educational Objectives

Upon completion of this activity, participants should be able to:

Advanced Renal Cell Carcinoma: CLEARing Up First Line Treatment

- Analyze the available literature for combination tyrosine-kinase inhibitors (TKI) and immunotherapy (IO) in adult patients with advanced renal cell carcinoma (RCC)
- Compare first-line treatment options for advanced RCC to highlight key differences which may impact treatment decisions
- Identify significant toxicities with TKIs and IO in patients receiving treatment for advanced RCC and appropriate drug therapy modifications

Treatment of BRAF V600E Mutated and HER2-amplified Metastatic Colorectal Cancer

- Review updates in treatment recommendations for adult patients with HER2-positive or BRAF V600E mutated metastatic colorectal cancer.
- Analyze available literature supporting the use of HER2 and BRAF targeted therapies in advanced colorectal cancer and discuss the clinical implications of targeted treatment.

Be the MONARCH of your own DESTINY: Recent Updates in Breast Cancer

- Review updates in metastatic HER2+ and adjuvant hormone-receptor positive breast cancer treatment
- Analyze the newly published DESTINY-Breast03 and monarchE trials

Targeted Therapies for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

- Review current guidelines for frontline treatment of CLL
- Analyze recent literature regarding use of BTK and BCL2 inhibitors for frontline CLL
- Evaluate the role of anti-CD20 monoclonal antibodies (mAbs) in combination with targeted inhibitors of BTK and BCL2 for the treatment of frontline CLL
- Discuss practical management of drug interactions and adverse effects associated with BTK and BCL2 inhibitors
- Describe future directions regarding the use of targeted therapies in CLL

Expanding Options for Patients with Relapsed/Refractory Multiple Myeloma

- Evaluate the utility of anti-CD38 monoclonal antibodies in newly diagnosed multiple myeloma patients
- Recognize novel therapeutic targets for drugs used in patients with relapsed/refractory multiple myeloma
- Create individualized supportive care plans for patients receiving novel therapy in the relapsed/refractory setting

A Different EGFR Mutation (EGFR Exon 20) Requires New Treatment Approaches in NSCLC

- Outline the current treatment options for patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation with progression on or after platinum-based chemotherapy.
- Compare and contrast the efficacy and safety of amivantamab and mobocertinib in patients with NSCLC exon 20 insertion mutation
- Utilize patient and treatment specific factors to determine optimal treatment strategy in patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutation with progression on or after platinum-based chemotherapy.

Integrative Medicine In Cancer Care: Optimizing Your Patients Experience

- Define Integrative Oncology and the benefits for the health, quality of life and patient outcomes across the cancer care continuum.
- Describe the development and implementation of an Integrative Oncology Department within an outpatient community cancer center.
- Categorize examples of complementary therapies outlining benefits and implications for cancer patients.
- Describe one example of a complementary therapy and how it is used to address patient symptoms resulting from conventional treatments.

Faculty and Disclosure of Conflicts of Interest

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The *faculty* reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty	Relevant Financial Relationships
Stephen C. Farley, PharmD, BCOP, Geisinger	Has no relevant financial relationships with ineligible companies to disclose.
David Hughes, PharmD, BCOP, Boston Medical Center	Has received consultant/advisor/speaker fees from Abbvie, Karyopharm, and Amgen.
Ticiana Leal, MD, Emory Winship Cancer Center	Has received consultant/advisor/speaker fees from Jazz, AstraZeneca, EMD Serono, Merck, Genentech, Boehringer-Ingelheim, Blueprint, Bayer, Lilly, Janssen, Mirati, Daichii-Sankyo, Takeda, Eisai, Novocure, Amgen, and Roche.
Alyson Leonard, PharmD, BCPS, BCOP, CPP, Cone Health	Has received consultant/advisor/speaker fees from Sanofi Genzyme.
Sagar Lonial, MD, FACP, Winship Cancer	Has received consultant/advisor/speaker fees from Novartis, Amgen, Janssen, Takeda, GSK, BMS, and Celgene.

Alison Palumbo, PharmD, MPH, BCOP, Oregon State University College of Pharmacy	Has received consultant/advisor/speaker fees from Oncology Reimbursement Management and Dedham Group.
Jasmine V. Patel, PharmD, BCOP, Boston Medical Center	Has received an education grant from Pfizer and has participated on an advisory board for Myovant.
Tashia Prince-Lacombe, MSN, AGNP-BC, Boston Medical Center	Has no relevant financial relationships with ineligible companies to disclose.
Latha Radhakrishnan, PharmD, BCPS, BCOP, University of Illinois Cancer Center	Has received consultant/advisor/speaker fees from Exelixis, Taiho, Regeneron, and AstraZeneca.
Makenna Smack, PharmD, BCOP, MD Anderson	Has no relevant financial relationships with ineligible companies to disclose.
Taylor Weis, PharmD, BCOP, Memorial Sloan Kettering	Has no relevant financial relationships with ineligible companies to disclose.
Dwinelva Zackery, LCSW, LISW-S, RYT, CHC, St. Elizabeth Cancer Center	Has no relevant financial relationships with ineligible companies to disclose.

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The NCODA planners and others no relevant financial relationship(s) to disclose with ineligible companies.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and NCODA. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education*

PACE designates this live activity for a maximum of 6 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education*

The maximum number of hours awarded for this Continuing Nursing Education activity is 6 contact hours.

Individual Session Credits

- Advanced Renal Cell Carcinoma: CLEARing Up First Line Treatment – 1.0 CME credit/CNE contact hour
- Treatment of BRAF V600E Mutated and HER2-amplified Metastatic Colorectal Cancer – 0.5 CME credit/CNE contact hour
- Be the MONARCH of your own DESTINY: Recent Updates in Breast Cancer – 0.5 CME credit/CNE contact hour
- Targeted Therapies for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL) – 1.0 CME credit/CNE contact hour
- Expanding Options for Patients with Relapsed/Refractory Multiple Myeloma – 1.0 CME credit/CNE contact hour

- A Different EGFR Mutation (EGFR Exon 20) Requires New Treatment Approaches in NSCLC – 1.0 CME credit/CNE contact hour
- Integrative Medicine In Cancer Care: Optimizing Your Patients Experience – 1.0 CME credit/CNE contact hour

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Instructions for Credit

CE Credit for the 2022 NCODA Spring Forum can be claimed through the LecturePanda platform. To register, please visit <https://www.lecturepanda.com/r/SpringForum2022>